2014

The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?

Jonathan S. Boomer
Washington University School of Medicine in St. Louis

Jonathan M. Green
Washington University School of Medicine in St. Louis

Richard S. Hotchkiss
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The changing immune system in sepsis
Is individualized immuno-modulatory therapy the answer?

Jonathan S Boomer1,*, Jonathan M Green1, and Richard S Hotchkiss2
1Department of Internal Medicine; Washington University School of Medicine; St. Louis, MO USA; 2Department of Anesthesiology, Medicine, and Surgery; Washington University School of Medicine; St. Louis, MO USA

Keywords: sepsis, immune therapy, cell exhaustion, immune suppression, adaptive immunity

Abbreviations: MDSC, myeloid derived suppressor cells; APC, antigen presenting cells; Th1, T lymphocyte type 1; Th2, T lymphocyte type 2; Treg, regulatory T cell; SIRS, systemic inflammatory response syndrome; VAP, ventilator-associated pneumonia; PD-1, programmed death receptor 1; PD-L, programmed death ligand; BTLA, B and T lymphocyte attenuator; HVEM, herpesvirus entry mediator; MODS, multi-organ dysfunction syndrome; ARDS, adult respiratory distress syndrome; PAMPs, pathogen-associated molecular patterns; DAMPs, danger-associated molecular patterns; PRRs, pattern recognition receptors; TLR, toll-like receptor; CTL, cytotoxic T lymphocyte; DC, dendritic cell; CARS, compensatory anti-inflammatory response syndrome; PBMCs, peripheral blood mononuclear cells; LCMV, lymphocytic choriomeningitis virus; ICU, intensive care unit; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor; NCI, National Cancer Institute; TIM-3, T cell membrane protein-3; LAG-3, lymphocyte-activation gene-3

Sepsis remains the leading cause of death in most intensive care units. Advances in understanding the immune response to sepsis provide the opportunity to develop more effective therapies. The immune response in sepsis can be characterized by a cytokine-mediated hyper-inflammatory phase, which most patients survive, and a subsequent immune-suppressive phase. Patients fail to eradicate invading pathogens and are susceptible to opportunistic organisms in the hypo-inflammatory phase. Many mechanisms are responsible for sepsis-induced immuno-suppression, including apoptotic depletion of immune cells, increased T regulatory and myeloid-derived suppressor cells, and cellular exhaustion. Currently in clinical trial for sepsis are granulocyte macrophage colony stimulating factor and interferon gamma, immune-therapeutic agents that boost patient immunity. Immuno-adjuvants with promise in clinically relevant animal models of sepsis include anti-programmed cell death-1 and interleukin-7. The future of immune therapy in sepsis will necessitate identification of the immuno-logic phase using clinical and laboratory parameters as well as biomarkers of innate and adaptive immunity.

Introduction

Sepsis is the major cause of death in most intensive care units in the United States with approximately a quarter of a million deaths annually. Although new treatment algorithms focusing on rapid administration of broad spectrum antibiotics and aggressive restoration of tissue oxygen delivery have led to decreases in mortality, the death rate is still 30%.1,2 Microbial virulence factors, the extent of bacterial tissue invasion, and patient co-morbidities interact to drive the host response that includes a wide array of manifestations including septic shock, adult respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), and systemic inflammatory response syndrome (SIRS).3,4 The heterogeneity of the disease encompasses a diverse interplay between immunological stimulation, systemic inflammation, and coagulopathy which vary in degree from patient to patient.5 This heterogeneity in patient response to sepsis is in part responsible for the over 30 failed clinical drug trials; beyond supportive care, there is presently no specific Food and Drug Administration-approved drug for the treatment of sepsis in humans.6 In this review we will focus on (1) the role of the adaptive immune system and detail its contribution to the host response in sepsis and (2) outline novel potential targets for individualized immune therapy in these patients.

Pro-Inflammatory Response: Cytokine Storm

Septic patients frequently present with fever, shock, and respiratory failure due to an uncontrolled pro-inflammatory response that has been termed SIRS.7 This initial immune recognition response is mediated by pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) originating from bacterial or fungal organisms and the host upon injury, respectively, that bind pattern recognition receptors expressed on innate immune cells.3,4,5 The activation of pattern recognition receptors results in the production of numerous pro-inflammatory molecules including TNF-α, IL-1β, IL-2, IL-6, IL-8, and IFN-γ and anti-inflammatory cytokines that induce a panoply of cellular responses and counter-responses. These responses include but are not limited to enhanced phagocytic activity, vascular endothelial injury with capillary leak, synthesis of acute phase proteins by the liver, chemotaxis of leukocytes to sites of infection/inflammation, and activation of the coagulation system.3,4,6,9
The coagulation system is closely linked to inflammation predominantly through the innate immune response. In sepsis, inflammation is accompanied by coagulation activation, thrombin generation, and disseminated intravascular coagulation (DIC). The primary coagulation pathway activated in sepsis is the tissue factor pathway which results in upregulation on monocyte/macrophage membranes and damage to the endothelium. The intrinsic or contact factor pathway amplifies clotting in an autoactivation manner leading to widespread vasodilation and generation of bradykinin. Ultimately, the rapid consumption of coagulation factors leads to diffuse hemorrhaging in sepsis. Protease-activated receptors on activated endothelial cells, neutrophils, and monocytes bind to thrombin, factor Xa, and tissue factor:VIIa which increases the synthesis of pro-inflammatory mediators IL-6, IL-8, and adhesion molecules. This adhesion molecule expression on the vasculature recruits activated leukocytes, in particular activated neutrophils which produce lytic enzymes, reactive oxygen species, and nitrogen intermediates that contribute to microcirculatory and organ failure.

Initially the pro-inflammatory response was believed to be the major cause of mortality in sepsis and was heavily targeted for therapeutic intervention. Clinical trials included, for example, TNF and IL-1β antagonists, toll-like receptor (TLR) blockers, platelet activating factor inhibitors (Xigris), anti-coagulants, endotoxin antagonists, hemofiltration to remove soluble endotoxin and cytokines, and blocking super-antigens which ultimately showed no benefit or, in some cases, worsened outcome.

**Hypo-Inflammatory Response: Immuno-Paralysis**

As patients survived the initial hyper-inflammatory, cytokine storm phase of sepsis, it became apparent that many septic patients developed a delayed and potentially prolonged counter-regulatory, anti-inflammatory state. This was initially referred to as a compensatory anti-inflammatory response syndrome (CARS). After considerable debate, a consensus developed that, sepsis can evolve into two phases: the first being hyper-inflammation (cytokine storm) and the second being hypo-inflammation (immune-paralysis) (Fig. 1). Although inflammation in sepsis is presented as a biphasic view in this review, genome-wide transcription profiling in human sepsis has indicated that mechanisms of pro- as well as anti-inflammatory mechanisms occur during variable times over the course of sepsis. However for the purpose of this review, the biphasic model explains the net effect on the inflammatory response, including both innate and adaptive immune function, where patients may cycle through each phase multiple times over the course of sepsis. This biphasic view maybe a simplistic explanation of a complex disease, yet provides a rational explanation for how the function of the immune system becomes altered during the course of sepsis. The intensity of the initial hyper-inflammatory phase varies depending upon a multitude of factors including the patient’s underlying physical state and co-morbidities, pathogen virulence factors, pathogen load, and genetic factors. Following this, perhaps in an effort to dampen systemic inflammation, subsequent immunosuppression may develop. As with the uncontrolled initial inflammation, this may overshoot and result in immune dysfunction that leads to increased host susceptibility to secondary bacterial infections (ventilator-associated pneumonia [VAP]), infections with typically avirulent or opportunistic organisms, reactivation of latent herpes viruses (cytomegalovirus [CMV]), increased risk of MODS, and loss of delayed type hypersensitivity response to common recall antigens. Research by many groups has shown that hypo-inflammation is due to a variety of immune defects including a dysfunctional adaptive immune response.

The adaptive immune system consists of specialized cells that are antigen specific and critical for generating memory and recall responses to antigens. Antigen-specific T cells are necessary for driving specific responses against intracellular (T-helper 1 [Th1]) or extracellular pathogens (T-helper 2 [Th2]) by cell-to-cell contact mechanisms or through soluble mediators (cytokines). CD4 T cells are typically classified as helper T cells and control cells of the adaptive system. CD8 T cells are classified as cytotoxic (CTL) and kill targeted cells such as virally infected or tumor cells. Antibody production, termed humoral
immunity, by B cells requires T-cell help. Antigen-specific antibody can neutralize toxins, fix complement, and coat the surface for phagocytic uptake of pathogens by monocytes/macrophages. Antigen-presenting cells, including monocyte/macrophages and dendritic cells, sample the environment and present antigens to T cells for initiation of immune responses or induction of tolerance of the adaptive immune response. The effects of sepsis on the adaptive immune response and the potential therapeutic advantage of targeting these components during the pathogenesis of sepsis will be the focus of the following sections.

**Adaptive Immunity: Apoptosis of Immune Effector Cells**

Programmed cell death, also called apoptosis, is one way in which the immune system maintains homeostasis by eliminating activated cells. Central to apoptosis are caspases which are cysteine proteases that degrade cellular proteins and NFκB, a transcription factor which will activate transcription of both pro-apoptotic and pro-survival genes. While the hyper-inflammatory response of sepsis requires NFκB for production of pro-inflammatory cytokines and IL-1β activation by caspase cleavage, both NFκB and caspases concurrently induce apoptosis of adaptive immune cells. Consistent with this, a concurrent apoptotic response has been shown to be present in sepsis in association with the pro-inflammatory response. Our group has shown both in mouse models of sepsis as well as most recently in patients with severe sepsis that there is a profound depletion of T, B, and dendritic cells. Within the first 24 h of sepsis diagnosis in humans, marked lymphopenia occurs which is due to recruitment of lymphocytes from the circulation to sites of inflammation/infection and to apoptotic depletion of CD4 and CD8 T cells in the blood. Postmortem analysis of spleens and lymph nodes from individuals who succumbed to sepsis confirmed the highly significant loss of CD4 and CD8 T cells. Memory CD8 T cells are highly susceptible to apoptosis in systemic inflammatory states such as septic shock and are depleted in sepsis. These results indicate that depletion of adaptive immune cells is a major pathologic component of sepsis with potential debilitating effects on host immunity.

Although the depletion of adaptive immune cells is recognized as an important part of the pathology of sepsis, the mechanisms responsible for this are not totally understood. In general apoptosis is divided into two mechanistic pathways, i.e., an extrinsic pathway that conveys a signal through a death receptor such as the tumor-necrosis family of receptors (i.e., CD95/CD95L, TNF/TNFR) or an intrinsic pathway that disrupts mitochondrial integrity resulting in release of cytochrome C. The activation of caspase 8, through death domains, and/or the activation of caspase 9, by the release of cytochrome C, results in the cleavage and activation of caspase 3 an effector caspase that induces extensive substrate cleavage of many critical proteins ultimately leading to cell death. These pathways of apoptosis have multiple points of crosstalk. Bid, a member of the Bcl-2 family of proteins, is cleaved by activated caspase-8, an effector of the extrinsic pathway, to form truncated Bid. This truncated Bid translocates to the mitochondrion where it binds Bax/Bak, members of the Bcl-2 family associated with the intrinsic pathway, to further induce apoptosis. Heat-shock proteins can either be constitutively expressed or rapidly induced in response to stress, like inflammation, yet modulate both the mitochondrial and receptor mediated apoptotic pathways. Adaptor molecules like receptor interacting protein (TRAF) or members of the TNF receptor-associated factor family (TRAF) activate transcription factor families associated with both survival and apoptosis including NFκB and mitogen-activated protein kinase (MAPK) pathways. To add to this complexity, a wide range of protein modifications and interactions form diverse yet interconnected signaling cascades that regulate signaling pathways such as PI3K-Akt/PKB, Ras-Raf-Mek-Erk MAPK, NFκB, and protein kinase C that are pro-survival while JNK/p38 stress MAPK or ROS/ceramide-mediate signaling which are pro-apoptotic.

As noted earlier, CD4 and CD8 T cells are highly susceptible to sepsis-induced apoptosis. To test the premise that soluble factors induce lymphocyte apoptosis in sepsis, serum from patients with SIRS was added to cultures of lymphocytes from healthy volunteers. Apoptosis of CD4 T cells was observed when plasma from SIRS patients was added but apoptosis was not present when serum from healthy donors was used. Although this soluble factor has yet to be identified, it is likely that a multitude of soluble factors are involved in modulating lymphocyte apoptosis. Some gram-positive bacteria have a unique property, an exotoxin termed a superantigen that activates CD4 T cells through a tetrad signaling complex consisting of a correctly folded superantigen, the CD28 dimer interface, VB loop of the TCR, and a binding site outside the epitope presenting groove on MHC class II molecules. This interaction occurs independent of MHC-Class II molecules and results in rapid activation, secretion of pro-inflammatory cytokines and ultimately cell death. In polymicrobial sepsis the activation of the peroxisome proliferator activated receptor (PPARγ) leads to decreased IL-2 gene expression, a T-cell survival factor that induces expression of the potent anti-apoptotic protein Bcl-2. The massive release of TNF-α early in sepsis results in activation of additional pro-inflammatory cytokines and chemokines which act in conjunction with TNF-α to induce T-cell apoptosis. In mouse models of sepsis, the complement factor C5a binds to the receptor C5aR on thymocytes and induces apoptosis. Therefore, in sepsis a diversity of soluble factors are present that potentially regulate apoptosis and add to the heterogeneity of sepsis pathology.

Lymphocyte fate is determined by the balance of pro- vs anti-apoptotic mechanisms. In our postmortem study of sepsis, we documented decreased expression of CD28 on T lymphocytes on septic patients when compared with control patients. The co-stimulatory molecule CD28, when engaged by B7 molecules on antigen presenting cells, is an essential requirement for IL-2 production and Bcl-2 expression, both pro-survival factors of T cells. Antigen-presenting cells, including dendritic cells and monocytes/macrophages, isolated from either the spleen or the lung of septic patients also had decreased expression of B7 molecules (B7-1/CD80 and B7-2/CD86) potentially limiting the ability of T cells to receive co-stimulation. Without the necessary
co-stimulation through CD28/B7 when the T-cell receptor engages antigen, T cells will undergo a process termed death by neglect or become functionally unresponsive (anergic).

Our recent studies have also indicated that T cells upregulate surface receptors that inhibit T-cell functions. We identified increased expression of programmed death receptor-1 (PD-1), CTLA-4, and B and T lymphocyte attenuator (BTLA) on T cells when isolated from postmortem spleen and lung as well as from blood 7 days after initial diagnosis with sepsis.45-46 Furthermore, we detected increased expression of the ligands for PD-1, programmed death ligand-1 and -2 (PD-L1 and PD-L2), on antigen-presenting cells isolated from the blood after 7 days of initial septic diagnosis and from lymphocytes isolated from post-mortem spleen and lung.45-46 The expression of PD-L and herpesvirus entry mediator (HVEM), the ligand for BTLA, was observed on the epithelium and on macrophages of the lung in septic patients.45,46 The expression of PD-L on antigen presenting cells and endothelial cells has been associated with the induction of tolerance,61,62 providing a mechanism where the tissue regulates lymphocyte homeostasis. The engagement of PD-1, CTLA-4, or BTLA, all members of the CD28-superfamily of receptors, results in T-cell apoptosis or cellular unresponsiveness that aid in returning the host to immune homeostasis.63 PD-L and CTLA-4 as well as TNFR ligand family members such as Fas-Ligand (CD95L) are expressed on a specialized type of CD4 T cell that expresses the transcription factor FoxP3 and high surface levels of CD25 (IL-2Rα) termed regulatory T cells (Tregs).64 Regulatory T cells are capable of suppressing T-cell proliferation, cytokine secretion and induce T-cell apoptosis.65 These cells are increased in percentage in septic patients due to their resistance to apoptosis and a decrease in CD4+CD25+ T cells35,36,45,66,67 provides yet another potential mechanism of immune dysfunction. The expression of these inhibitory receptors/ligands on T cells, antigen presenting cells and tissue presents an environment that is conducive to T-cell depletion and unresponsiveness in septic patients.

**Adaptive Immunity: Cellular Hypo-Responsiveness**

The anti-inflammatory cytokine IL-10 has been detected in serum of septic patients very early during their illness.68 A high ratio of IL-10 to TNF-α in septic patients correlated with mortality in patients with community acquired infection.68,69 The anti-inflammatory cytokine IL-10 is produced by Tregs and Th2 type cells and suppresses the Th1 (CD8 T cell) response further potentiating an anti-inflammatory environment.70-71 This suppressive environment results in a marked decrease in stimulated monocyte production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 (typically less than 10−20% that of healthy controls).72-76 This compensatory anti-inflammatory response syndrome, or immune paralysis as it was originally referred to, is mediated by a predominance of a Th2 response, increased Tregs, apoptosis of lymphocytes and decreased MHC class II (HLA-DR) molecules on monocytes/macrophages.10,18 Our group reported that immune effector cells isolated from postmortem spleens with patients dying of sepsis and peripheral blood mononuclear cells isolated from blood of septic individuals 7 days after onset of sepsis have impaired secretion of both pro- and anti-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10).45,46 Furthermore, this cytokine secretion defect in septic patients was present after stimulation with lipopolysaccharide (a monocyte/macrophage activator) and after stimulation with anti-CD3/anti-CD28 (a T-cell activator) indicating that both the innate and adaptive immune systems are suppressed.45,46

**Adaptive Immunity: Cellular Exhaustion**

Both the postmortem and prospective blood study, previously discussed, demonstrated that T lymphocytes from septic patients expressed inhibitory receptors and that these T cells were unable to produce cytokines after ex vivo stimulation.45,46,77 In the post-mortem study, T cells isolated from the spleen had increased expression of CD69, PD-1, and CD25 and decreased expression of the IL-7 receptor (IL-7R, CD127) and CD28 when compared with age-matched controls.46 T cells isolated from the lung had increased expression of PD-1 and BTLA indicating a degree of tissue specificity in sepsis.45 Furthermore, increased expression of inhibitory receptors, PD-1, BTLA, CTLA-4, T cell membrane protein-3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), and decreased expression of the IL-7R on T cells isolated from the blood of septic patients occurs over the course of sepsis.45 This expression of inhibitory receptors and decreased cytokine secretion resemble a recently described phenotype observed in chronic viral infections like HIV and hepatitis C that is termed cellular exhaustion.

T-cell exhaustion is a step-wise progressive loss of T-cell functions in the presence of high antigen load that can result in T-cell deletion.78 Originally described in the lymphocytic choriomeningitis virus (LCMV) mouse model, T-cell exhaustion has also been documented in HIV, hepatitis C, hepatitis B, polypoma virus, adenovirus, Friend leukemia virus, and in malignancies.78 Exhausted T cells have high expression of CD69, CD43 (1B11), PD-1, TIM-3, and LAG-3, low expression levels of CD62L and CD127 (IL-7R), increased expression of the transcription factor BLIMP-1 (CD8 T cells) and decreased secretion of TNF-α, IL-2, IFN-γ, and Granzyme B.79 The engagement of PD-1 by its ligands on exhausted T cells results in IL-10 production, functional unresponsiveness and/or apoptosis.78 In sepsis, there is high antigen load due to chronic infection, T cells acquire expression of inhibitory receptors over time, as well as the expression of inhibitory ligands on antigen presenting cells and in a tissue-specific manner, provide a unique environment for T-cell exhaustion as an additional mechanism of immune suppression in sepsis.45,46 In support of this concept of sepsis-induced T-cell exhaustion, tissue expression of PD-L and HVEM the ligands for PD-1 and BTLA on T cells was present in the lungs of septic individuals but not in lungs of transplant recipients or age-matched non-septic control patients.46 These findings are particularly relevant given the high incidence of ventilator associated pneumonia which is the most common nosocomial infection in the intensive-care unit.79-81 The increased susceptibility of the lung to secondary infection in septic patients may be due
Thus far, the focus of enhancing immune function in sepsis has been limited to trials for GM-CSF or G-CSF, a stimulator of the innate immune system, and IFN-γ, a stimulator of the adaptive immune system. Despite active research in understanding human sepsis, the number of registered human clinical trials is disappointing, with most observational in nature and few being interventional (Table 1). Many septic patients have a relatively short-lived hyper-inflammatory phase; therefore, the success of drugs targeting inflammation has only a narrow time frame to be effective. The keys to drugs targeting this hyper-inflammation are: drugs with elevated levels of pro-inflammatory cytokines (i.e., TNF-α, IL-1β, or IL-6).54 Phase I–III clinical trials using drugs to reduce this pro-inflammatory cascade have had disappointing results in 28-day mortality rates in septic patients when compared with placebo-treated controls.14,17,82-90 Most septic patients residing in ICUs have survived the hyper-inflammatory stage of the disease yet have prolonged periods of hospitalization and recovery with the potential to become immune compromised and develop nosocomial infections and/or multiorgan dysfunction.34,91,92 Therefore, one of the keys to decreasing mortality in sepsis may be the development of therapies to augment host immune responses. Collectively, results of studies designed to block this hyper-inflammatory phase suggest partial benefit in early onset sepsis in highly-defined populations of septic patients yet are potentially detrimental to septic patients who have progressed into immune-paralysis.15,33

Even before the molecular pathophysiology of sepsis was thoroughly understood, investigators attempted to stimulate the innate and adaptive immune systems with IFN-γ, granulocyte macrophage colony stimulating factor (GM-CSF) or granulocyte colony stimulating factor G-CSF. In an attempt to reverse monocyte/macrophage dysfunction and increase IL-17, a cytokine necessary for the recruitment of neutrophils to the infected site, septic patients were treated with IFN-γ.93 Treatment with GM-CSF was also predicted to reverse the dysfunction of dendritic cells and macrophages/monocytes.94 G-CSF was utilized to increase numbers of polymorphonuclear leukocytes, in an effort to enhance pathogen clearance. Although a recent meta-analysis performed on GM-CSF and G-CSF studies conducted from 1998 to 2011 failed to show survival benefit,95 some studies did show limited efficacy on research endpoints.96-105 In summary, GM-CSF or G-CSF treatment increased neutrophil phagocytosis, resolved infections earlier, decreased secretion of toxic metabolites, increased expression of CD11b and HLA-DR on neutrophils/monocytes, and reversed immune-paralysis in selected septic patients.54 Two recent small phase 2 trials of GM-CSF that have targeted its use to septic patients with low monocyte HLA-DR expression have shown benefit. Mechanically-ventilated patients with sepsis that received GM-CSF had improved health evaluation scores, shortened time of mechanical ventilation, and an

### Table 1. Immune enhancing therapy: clinical trials in sepsis

<table>
<thead>
<tr>
<th>Agent</th>
<th>Study</th>
<th>Outcomes</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-CSF</td>
<td>RCT in patients with pneumonia and severe sepsis</td>
<td>Increased WBC counts</td>
<td>Root et al.103</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No reduction in mortality</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Well tolerated</td>
<td></td>
</tr>
<tr>
<td>G-CSF</td>
<td>RCT in patients with multilobar pneumonia</td>
<td>Increased WBC counts</td>
<td>Nelson et al.101</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reduction in mortality (trend)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Well tolerated</td>
<td></td>
</tr>
<tr>
<td>GM-CSF</td>
<td>RCT in patients with sepsis or septic shock and sepsis induced immunesuppression</td>
<td>Increased HLA-DR expression</td>
<td>Meisel et al.105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restored cytokine secretion in monocytes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Improved patient outcomes</td>
<td></td>
</tr>
<tr>
<td>GM-CSF, rIFN-γ (ongoing)</td>
<td>Effects of immunostimulation with GM-CSF or IFN-γ on immunoparalysis following human endotoxemia</td>
<td>Cytokine secretion by lymphocytes</td>
<td>NCT01374711</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HLA-DR expression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monocyte/neutrophil function</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphocyte gene expression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Voluntere responses</td>
<td></td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>RCT in trauma patients</td>
<td>Increased HLA-DR expression</td>
<td>Polk et al.106</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decreased severe infections (trend)</td>
<td></td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>RCT in patients with burns</td>
<td>No improved patient outcomes</td>
<td>Wasserman et al.107</td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>RCT in trauma patients</td>
<td>Reduced infection related deaths</td>
<td>Dries et al.108</td>
</tr>
<tr>
<td>rIFN-γ (ongoing)</td>
<td>Effects of interferon-gamma on sepsis-induced immunoparalysis</td>
<td>Cytokine secretion by lymphocytes</td>
<td>NCT01649921</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HLA-DR and receptor expression (PD-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphocyte gene expression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reversibility of monocyte dysfunction</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient outcomes</td>
<td></td>
</tr>
</tbody>
</table>

Thus far, the focus of enhancing immune function in sepsis has been limited to trials for GM-CSF or G-CSF, a stimulator of the innate immune system, and IFN-γ, a stimulator of the adaptive immune system. Abbreviations: RCT, randomized controlled trial; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; rIFN-γ, recombinant interferon gamma; PD-1, programmed death receptor-1; WBC, white blood cell count; NCT, ClinicalTrials.gov identifier.

**Immuno-Therapy: Targeting the Adaptive Immune System**

In part to expression of inhibitory ligands on lung parenchyma resulting in local T-cell exhaustion.

**Immuno-Therapy: Targeting the Adaptive Immune System**

Despite active research in understanding human sepsis, the number of registered human clinical trials is disappointing, with most observational in nature and few being interventional (Table 1). Many septic patients have a relatively short-lived hyper-inflammatory phase; therefore, the success of drugs targeting inflammation has only a narrow time frame to be effective. The keys to drugs targeting this hyper-inflammation are: drugs should be short lived, applied early and used only in patients with elevated levels of pro-inflammatory cytokines (i.e., TNF-α, IL-1β, or IL-6).54 Phase I–III clinical trials using drugs to reduce this pro-inflammatory cascade have had disappointing results in 28-day mortality rates in septic patients when compared with placebo-treated controls.14,17,82-90 Most septic patients residing in ICUs have survived the hyper-inflammatory stage of the disease yet have prolonged periods of hospitalization and recovery with the potential to become immune compromised and develop nosocomial infections and/or multiorgan dysfunction.34,91,92 Therefore, one of the keys to decreasing mortality in sepsis may be the development of therapies to augment host immune responses. Collectively, results of studies designed to block this hyper-inflammatory phase suggest partial benefit in early onset sepsis in highly-defined populations of septic patients yet are potentially detrimental to septic patients who have progressed into immune-paralysis.15,33

Even before the molecular pathophysiology of sepsis was thoroughly understood, investigators attempted to stimulate the innate and adaptive immune systems with IFN-γ, granulocyte macrophage colony stimulating factor (GM-CSF) or granulocyte colony stimulating factor G-CSF. In an attempt to reverse monocyte/macrophage dysfunction and increase IL-17, a cytokine necessary for the recruitment of neutrophils to the infected site, septic patients were treated with IFN-γ.93 Treatment with GM-CSF was also predicted to reverse the dysfunction of dendritic cells and macrophages/monocytes.94 G-CSF was utilized to increase numbers of polymorphonuclear leukocytes, in an effort to enhance pathogen clearance. Although a recent meta-analysis performed on GM-CSF and G-CSF studies conducted from 1998 to 2011 failed to show survival benefit,95 some studies did show limited efficacy on research endpoints.96-105 In summary, GM-CSF or G-CSF treatment increased neutrophil phagocytosis, resolved infections earlier, decreased secretion of toxic metabolites, increased expression of CD11b and HLA-DR on neutrophils/monocytes, and reversed immune-paralysis in selected septic patients.54 Two recent small phase 2 trials of GM-CSF that have targeted its use to septic patients with low monocyte HLA-DR expression have shown benefit. Mechanically-ventilated patients with sepsis that received GM-CSF had improved health evaluation scores, shortened time of mechanical ventilation, and an
accompanied increased HLA-DR expression and in secretion of pro-inflammatory cytokines (IL-6 and TNF-α) ex vivo as compared with controls. At least 2 clinical trials of GM-CSF are currently enrolling patients in sepsis (NCT01374711 and NCT01653665, Table 2), so it will be highly interesting to observe these results when they become available.

Thus far, the only attempt to modulate the adaptive immune response in a sepsis clinical trial was the administration of IFN-γ (Table 2). Treatment with IFN-γ in critical illness has yielded conflicting results. In two multi-center trials with patients of trauma and burns, treatment with IFN-γ had no effect when compared with placebo. Interestingly, when IFN-γ was co-administered with GM-CSF to those septic patients whose monocytes had decreased HLA-DR expression of less than 35% of normal, therapy raised HLA-DR co-expression up to ~50% and restored TNF-α secretion from ex vivo stimulated peripheral blood mononuclear cells. These results further confirm the importance of knowing the relative pro- and anti-inflammatory balance of the septic patients before administering immune therapies in sepsis. In our prospective study of septic patients, IFN-γ was determined to be the cytokine that was significantly decreased at the earliest time point following sepsis onset. Furthermore, peripheral blood mononuclear cells isolated from septic individuals that were rested overnight in fresh media

Table 2. Clinical trials for the immune system in sepsis

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Title</th>
<th>Study type</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01600989</td>
<td>Mitochondrial Function of Immune Cells in Sepsis (MitoSepsis) (2012)</td>
<td>Observational</td>
<td>University Hospital Inselspital</td>
</tr>
<tr>
<td>NCT01530932</td>
<td>Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Vs. Abdominal Origin (2011)</td>
<td>Observational</td>
<td>University Hospital Mannheim</td>
</tr>
<tr>
<td>NCT00187824</td>
<td>Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis (2005)</td>
<td>Observational</td>
<td>University College London Hospital</td>
</tr>
<tr>
<td>NCT01410526</td>
<td>Assessment of Peritoneal Immune Response in Patients with Severe Intra-abdominal Sepsis Managed with Laparostomy and Vacuum Assisted Closure (VAC) (2011)</td>
<td>Observational</td>
<td>Aristotle University of Thessaloniki</td>
</tr>
<tr>
<td>NCT01472952</td>
<td>System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients (2011)</td>
<td>Observational</td>
<td>University Hospital Mannheim</td>
</tr>
<tr>
<td>NCT0155674</td>
<td>Innate Immune Functions of Immature Neutrophils (2010)</td>
<td>Observational</td>
<td>University Hospital Geneva</td>
</tr>
<tr>
<td>NCT01766414</td>
<td>In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia – VECTOR II (2013)</td>
<td>Interventional</td>
<td>Radboud University</td>
</tr>
<tr>
<td>NCT01649921</td>
<td>The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (2012)</td>
<td>Interventional</td>
<td>Radboud University</td>
</tr>
<tr>
<td>NCT00294697</td>
<td>Genetic Variation and Immune Response After Injury (2006)</td>
<td>Observational</td>
<td>National Institute of General Medical Sciences</td>
</tr>
<tr>
<td>NCT00638521</td>
<td>Immune-cell Membrane Trafficking (2008)</td>
<td>Observational</td>
<td>University of Washington</td>
</tr>
<tr>
<td>NCT01099813</td>
<td>Sepsis Pathophysiological and Organisational Timing (SPOT[Light]) (2010)</td>
<td>Observational</td>
<td>Intensive Care National Audit and Research Centre</td>
</tr>
<tr>
<td>NCT01756755</td>
<td>Endotoxin Adsorber Hemoperfusion and Microcirculation (2012)</td>
<td>Interventional</td>
<td>National Taiwan University Hospital</td>
</tr>
<tr>
<td>NCT01275976</td>
<td>Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients with a Femur Fracture (CAESAR) (2011)</td>
<td>Interventional</td>
<td>UMC Utrecht</td>
</tr>
<tr>
<td>NCT00527384</td>
<td>Biomarker Analysis of Stress (2007)</td>
<td>Observational</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>NCT01397058</td>
<td>Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress (RECYSTRESS) (2011)</td>
<td>Observational</td>
<td>University of Athens</td>
</tr>
<tr>
<td>NCT01374711</td>
<td>Effects of Immunostimulation with GM-CSF or IFN-γ on Immunoparalysis Following Human Endotoxemia (2011)</td>
<td>Interventional</td>
<td>Radboud University</td>
</tr>
</tbody>
</table>

A search on ClinicalTrials.gov was performed using the search terms “Sepsis and Immune” (48 studies) or “Sepsis and Biomarkers” (74 studies) filtered by “open studies”. This represents a list of the current open and enrolling clinical trials for sepsis in regards to the immune system. Interestingly, most clinical trials in sepsis have been initiated within the past 10 years as indicated by the start date of the clinical trial in parenthesis following the trial title.
recovered their ability to secrete IFN-γ in response to ex vivo stimulation.8 These data suggest depressed secretion of IFN-γ is an early indicator of hypo-inflammation and may be a reversible defect in lymphocytes; therefore, pathways that augment IFN-γ may be good potential therapeutic targets. Currently Radboud University in the Netherlands is conducting an IFN-γ trial in sepsis to study the effects on “sepsis-induced immunoparalysis”, which will be completed in December 2013 (ClinicalTrials.gov; NCT01649921).

In addition to GM-CSF, G-CSF, and IFN-γ, other novel immune-adjuvant therapies may be effective in augmenting the adaptive immune system and restoring immunity. The profound apoptosis-induced depletion of lymphocytes in sepsis is one such attractive therapeutic target. The pro-survival cytokines IL-7 and IL-15 have had promising results in sepsis models in preventing lymphocyte apoptosis and restoring adaptive immunity. In a mouse model of sepsis, IL-15 treatment increased lymphocyte survival, decreased apoptosis of natural killer cells, dendritic cells, and T cells, and increased IFN-γ secretion.10 The administration of IL-15 may have additional benefits of increasing natural killer and dendritic cell survival11,12 whereas IL-7 is thought to be a more T cell targeted cytokine.13

Currently, the most promising cytokine in restoring T-cell function in a variety of disease states is IL-7. IL-7 is a pluripotent cytokine of the immune system that affects both T and B cells and induces proliferation of naïve and memory T cells.13,14 Administration of IL-7 by investigators at the National Cancer Institute to cancer patients led to a doubling of CD4 and CD8 T cells, did not expand regulatory T cells, and led to a corresponding increase in spleen and lymphnodes by roughly 50%.15-17 Recombinant IL-7 was also effective in inducing a doubling of circulatory CD4 and CD8 T cells in patients with lymphopenia due to HIV.18 Several groups including ours have shown that IL-7 treatment of mouse models of sepsis results in increased lymphocyte numbers, restored delayed type hypersensitivity responses, decreased lymphocyte apoptosis, reversed the impaired IFN-γ secretion of lymphocytes and improved survival.19,20,21 Furthermore, work by Venet et al. showed that IL-7 treatment of isolated lymphocytes from septic patients restored T-cell proliferation, IFN-γ secretion, STAT5 phosphorylation (an important downstream signaling molecule of the IL-7R), and Bcl-2 expression close to that of healthy controls.19 Treatment of HIV and cancer patients with hIL-7 has indicated IL-7 is well tolerated with less side effects then IL-2, another pro-survival cytokine for T cells, and has diverse effects including: increases in T-cell survival, restores function in exhausted T cells a phenotype identified in sepsis,7 increases expression of adhesion molecules and therefore trafficking to sites of infection, and increases T cell receptor diversity thereby increasing pathogen recognition.18,122-124 Due to the diverse effects of IL-7 on the adaptive immune system and its good safety clinical profile, IL-7 has been consistently ranked as one of the top therapeutic molecules by NCI.15,25 Therefore, we believe clinical trials of IL-7 in sepsis should be initiated.

Common to most septic patients is increased expression of PD-1 on T cells over the progression from hyper-inflammation to hypo-inflammation. As noted earlier, signaling through PD-1 inhibits T-cell proliferation, induces IL-10 secretion, induces apoptosis and anergy, and inhibits cytotoxicity of CD8 T cells.126,127 Four independent groups have shown that disruption of the PD-1/PD-L axis either by genetic deletion or by pharmacologic manipulation improved survival in bacterial and fungal murine sepsis.128-131 In both our prospective and post-mortem studies of septic patients, PD-1 expression was increased on CD4 and CD8 T cells while PD-L expression was increased on antigen presenting cells as well as on the tissue of the spleen and lung indicating this PD-1/PD-L axis may be dysregulated in human sepsis. Furthermore, PD-1 overexpression on T cells from septic patients correlated with decreased T-cell proliferation, increased secondary infections and mortality.12 In oncology, anti-PD-1 and anti-PD-L antibody therapy has been used successfully to treat various tumors in 20–25% of treated patients.133,134 These data indicate that blocking the PD-1/PD-L axis is a promising target for restoring immune function in human sepsis.

As T-cell exhaustion is defined by the expression of multiple inhibitory receptors, not just PD-1 expression, the development of blocking antibodies to these additional receptors may also be promising in sepsis.7 For example the BTLA/HVEM axis also a negative regulator of T-cell responses135,136 is also present in human sepsis. Interestingly, T cells express BTLA while tissue of the lung, a common site of secondary nosocomial infections including ventilator-associated pneumonia, expresses HVEM.45,46 BTLA deficient mice have increased survival in a mouse model of sepsis,137 providing another immunologic target for ventilator associated pneumonia and sepsis. Additional receptors associated with T-cell exhaustion such as TIM-3, LAG-3, and CTLA-4 may also provide therapeutic targets in restoring T-cell functions. Cellular exhaustion is a characteristic not only of chronic viral infections but of cancer biology due to the presence of high antigen load.138 In mouse models of tumor formation, anti-TIM-3 therapy reduced tumor burden and increased IFN-γ secretion and cytotoxic ability of tumor-specific CD8 T cells.139,140 In addition to TIM-3, LAG-3 therapy has shown promising results in treating human cancers by restoring anti-tumor responses of T cells.141 With our rapidly expanding knowledge of T-cell exhaustion and the role of these inhibitory receptors in lymphocyte function, the potential for biologics that modulate the adaptive immune system and restore lymphocyte function in sepsis offers great promise (Fig. 2).

In the not too distant future, one can imagine a way to genetically manipulate T cells for the treatment of sepsis. Genetically modified T cells are currently in trial for the treatment of herpes viral infections in transplant patients (ClinicalTrials.gov; NCT01646645 and NCT01553885). These T cells have been manipulated to be specific against viral specific antigens.142 In sepsis, a modified T cell resistant to apoptosis and polyclonal for a variety of pathogens, including bacterial, fungal and viral, could be transfused during immune dysfunction to restore patient immunity. Preliminary evidence in mouse models of sepsis using genetically modified T cells that overexpress Bcl-2143-145 or Akt146 have resulted in increased T cell and mouse survival.
Modified T cells incorporating a suicide gene would enable only the modified T cells to be destroyed once the infection is cleared leaving the patient’s own immune system intact.147,148 This would eliminate a potential concern of autoimmunity from long-term antibody therapy.

**Final Thoughts: Immune-Enhancing Therapy**

Many trials using immune-modulatory agents have yielded discouraging results in human clinical trials for sepsis.3,4 One reason for this failure is that animal studies may not always correlate with the human condition. As the majority of sepsis models use genetically similar young mice, confounding problems that are often present in clinical sepsis like age, genetic diversity, underlying co-morbidities, various sites of infections, susceptibility to virulence factors, and management protocols including nutrition and antibiotic usage are not accounted for.3,4,149,150 This heterogeneity of human sepsis is in part what makes performing clinical trials and their success very difficult to achieve. Recently, genetic profiling of inflammatory diseases in humans and mice have indicated that mouse gene transcriptional changes occurring in sepsis do not correlate with the human condition.151 These data indicate the need to undertake more human translational approaches to better our understanding of the underlying molecular pathophysiology of sepsis (Table 1).

To monitor sepsis in humans, clinical trials are currently underway to elucidate biomarkers that can identify patients who have increased or decreased inflammation (ClinicalTrials.gov, Table 1). Importantly, the kinetics of expression of the targeted receptors (i.e., PD-1/PD-L, HVEM/BTLA) as well as patient’s immune status needs to be fully understood so that therapy can be employed effectively. For example, inhibition of IL-10 in patients with increased inflammation dramatically increased pro-inflammatory cytokines with detrimental effects.152 Clinical trials that monitored HLA-DR expression as an indicator of immune function had moderate success in improving outcomes in sepsis.105,109 Therefore, a combination of flow cytometry for lymphocyte expression of surface receptors (i.e., HLA-DR, PD-1), functional assays for cytokine secretion (IFN-γ) as well as presence or absence of nosocomial infections (ventilator...
pneumonia, *Candida* spp.) and reactivation of latent viruses (i.e., herpes viruses) may help to guide patient immune-therapy.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**References**


8. Manford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-21; PMID:11770909; http://dx.doi.org/10.1164/ajrccm.163.2.2007102


20. Manford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-21; PMID:11770909; http://dx.doi.org/10.1164/ajrccm.163.2.2007102


**Acknowledgments**

Supported in part by National Institutes of Health (NIH) grant GM09389 to J.M.G. and R.S.H. and Institute of Clinical and Translational Sciences (ICTS) award CTSA601 to J.S.B.


91. Balk RA. Pathogenesis and management of multiple virulence 55
89. Tumlin J, Wali R, Williams W, Murray P, Tolwani
88. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC,
87. Bellomo R, Tetta C, Ronco C. Coupled plasma filtration
84. Opal SM, Fisher CJ Jr., Dhainaut JF, Vincent JL,
82. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler
68. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6; PMID:15905493
60. Inoue S, Unisanger J, Davis CG, Muenzer JT, Ferguson TA, Chung K, Osborne DF, Clark AT, Cooperstein CM, McDunn JE, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010; 184:1401-9; PMID:20026757; http://dx.doi.org/10.4049/jimmunol.0902307
57. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6; PMID:15905493


Fin HJ, Jeong YH, Park HJ, Ha SJ. Mechanism of T cell exhaustion in a chronic environment. BMB Rep 2011; 44:217-31; PMID:21524364; http://dx.doi.org/10.5483/BMBRep.2011.44.4.217


June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1666-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446

June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117:1204-12; PMID:17476350; http://dx.doi.org/10.1172/JCI31446

Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(Suppl.3):S307-7; PMID:19104223; http://dx.doi.org/10.1097/01.CCM.000033181922b43

